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Abstract
Introduction—From 2004–2012, the Harvard/AIDS Prevention Initiative in Nigeria, funded 
through the US President’s Emergency Plan for AIDS Relief programme, scaled up HIV care and 
treatment services in Nigeria. We describe the methodologies and collaborative processes 
developed to improve laboratory capacity significantly in a resource-limited setting. These 
methods were implemented at 35 clinic and laboratory locations.
Methods—Systems were established and modified to optimise numerous laboratory processes. 
These included strategies for clinic selection and management, equipment and reagent 
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procurement, supply chains, laboratory renovations, equipment maintenance, electronic data 
management, quality development programmes and trainings.
Results—Over the eight-year programme, laboratories supported 160 000 patients receiving HIV 
care in Nigeria, delivering over 2.5 million test results, including regular viral load quantitation. 
External quality assurance systems were established for CD4+ cell count enumeration, blood 
chemistries and viral load monitoring. Laboratory equipment platforms were improved and 
standardised and use of point-of-care analysers was expanded. Laboratory training workshops 
supported laboratories toward increasing staff skills and improving overall quality. Participation in 
a World Health Organisation-led African laboratory quality improvement system resulted in 
significant gains in quality measures at five laboratories.
Conclusions—Targeted implementation of laboratory development processes, during 
simultaneous scale-up of HIV treatment programmes in a resource-limited setting, can elicit 
meaningful gains in laboratory quality and capacity. Systems to improve the physical laboratory 
environment, develop laboratory staff, create improvements to reduce costs and increase quality 
are available for future health and laboratory strengthening programmes. We hope that the 
strategies employed may inform and encourage the development of other laboratories in resource-
limited settings.
Introduction
Laboratories are fundamental and essential components of health systems, providing clinical 
staff and patients with test results that are the basis of disease diagnosis and treatment; yet, 
laboratories are often neglected by governments, development organisations and other 
stakeholders in plans to improve healthcare systems in developing countries. Despite the 
scale-up of global health programmes in the last decade, sub-Saharan Africa continues to 
suffer the consequences of operating with some of the most poorly-equipped and under-
resourced laboratories in the world.1 As such, by 2012, the US President’s Emergency Plan 
for AIDS Relief (PEPFAR) Blueprint, the World Health Organization (WHO) and the 
United Nations Millennium Development Goals (UNMDG) each called for strengthened 
national laboratory systems as a critical component of scaling up HIV and tuberculosis (TB) 
prevention and treatment programmes.2,3
Based on the Nigerian National HIV Sentinel Surveillance Surveys in 2005 and 2010, the 
national prevalence of HIV-1 has remained fairly stable at approximately 4%.4 The Harvard 
School of Public Health received PEPFAR funds from 2004 to 2012 to support the 
development of prevention, care and treatment programmes in Nigeria, Botswana and 
Tanzania. In Nigeria, Harvard partnered with the AIDS Prevention Initiative in Nigeria 
(APIN), an organisation developed through funding from the Bill and Melinda Gates 
Foundation from 2000–2006, to provide evidence-based HIV prevention in four states of the 
country. The Harvard/APIN PEPFAR programme was built upon this foundation of HIV 
prevention activities and initiated support of antiretroviral therapy (ART) activities at six 
tertiary-level facilities in 2004; this expanded to 35 clinics and laboratories by 2009. To 
ensure sustainability, Harvard helped to establish APIN Ltd./Gte. as an independent, 
Nigeria-based non-governmental organisation. Beginning in 2009, and fully completed in 
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February 2012, all Harvard/APIN PEPFAR programme activity was transitioned to APIN 
management.
From the beginning of the Harvard/APIN PEPFAR programme, it was determined that a 
fundamental component of the capacity-building efforts would be dedicated to laboratory 
infrastructure, with corresponding growth of logistics management for procuring supplies 
and laboratory staff training in order to ensure sustainability. In developing the programme 
frameworks and plans, we incorporated lessons learned from previously-developed ART 
laboratories in both Nigeria and Senegal so as to elicit lasting gains in laboratory capacity 
and infrastructure.5 In this report, we describe the organisational framework that resulted in 
the establishment of and continuous quality improvements to laboratory capacity in Nigeria 
over the eight years of the Harvard/APIN PEPFAR programme (2004–2012). We highlight 
the collaborative process, with details on specific strategies and methodologies, found to be 
essential for meaningful laboratory development in a resource-limited setting.
Research methods and design
Our programme’s laboratories were organised with large tertiary facilities at the centre, 
providing support to secondary hospitals and associated primary health clinics using a hub-
and-spoke model (Figure 1). Tertiary-level laboratories were associated with university 
teaching hospitals or research institutes with large HIV ART programmes. Secondary-level 
hospitals provided HIV serology, CD4+ cell count enumeration, haematology and clinical 
chemistry testing. They also had the capacity to store plasma samples for viral load (VL) 
testing, and dried blood spot (DBS) samples for early infant diagnosis, for up to two weeks 
before transport to an associated tertiary laboratory. Primary health clinics were smaller 
health centres that provided basic care, performed HIV rapid testing, drew blood samples for 
testing to be done elsewhere and referred patients to the secondary or tertiary medical 
facilities.
Clinic selection
The selection of a clinic or hospital for development of laboratory capacity to support HIV 
care was a complex process and required accounting for a number of factors, including 
patient burden, existing infrastructure, prior collaborations, geographic proximity to other 
programme facilities and local politics. The Harvard/APIN PEPFAR programme both 
consulted and collaborated with in-country partners and funding organisations so as to 
identify candidate clinics. After a clinic was proposed, a detailed site visit was performed to 
survey the existing laboratory, clinical and personnel infrastructure. There were often 
substantial obstacles to laboratory development as a result of the poor existing infrastructure, 
such as the lack of running water or dependable electrical service. Reliability of utilities was 
essential, as the programme’s protocol for laboratory testing was substantial, requiring 
electricity-driven instruments (Table 1).
Procurement of equipment
Preliminary laboratory improvements began with a needs assessment and included ensuring 
reliable water and electricity supply, back-up generator, security and adequate air-
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conditioning capacity. Whilst tertiary and secondary hospital laboratories had an existing 
patchwork of HIV diagnostics, clinical chemistry, haematology and CD4+ cell count 
analysers in place, the Harvard/APIN PEPFAR programme expanded and improved access 
to these critical technologies. In accordance with the WHO’s 2008 Maputo Declaration,6 we 
attempted to provide all laboratories with the same equipment manufacturer and models, 
supporting standardisation of platforms across sites. Standardisation of laboratory equipment 
allowed for streamlined training and maintenance, eased acquisition of spare parts and 
reduced overall costs through higher-volume orders. The availability of in-country servicing 
along with predicted sustainability of manufacturers, vendors and platforms, were also 
important factors in selection criteria.
For HIV testing, following the Nigerian national rapid test algorithm guidelines at the time, 
the Determine HIV rapid test (Alere Medical Co., Japan) was provided, followed by 
Unigold (Trinity Biotech PLC, Ireland), with Statpack (Chembio Diagnostic Systems, 
Medford, NY, United States) as the discordant result tiebreaker. If further HIV infection 
confirmation was required, Western blot (Immunetics, Boston, MA, United States) was 
performed. Immunologic monitoring of patients’ CD4+ cell counts was performed using the 
flow cytometry-based Cyflow Counter or Cyflow II (Partec GmbH, Munster, Germany) 
platform. To monitor virologic treatment response, HIV VLs were measured with the 
manual COBAS Amplicor HIV-1 Monitor test, version 1.5 (Roche Diagnostics GmbH, 
Mannheim, Germany). Eligibility for ART and subsequent toxicity were evaluated using 
relevant blood chemistry assays (Table 1) on the Roche COBAS C311, COBAS C111 or 
equivalent. Haematology monitoring was performed using the Mindray BC-3200 (Mindray 
Medical Ltd, Shenzen, China) or equivalent. HIV-1 drug resistance was evaluated, when 
indicated, using the Viroseq Genotyping System version 2.0 (Abbott Molecular, Des 
Plaines, IL, United States), with sequencing results being generated on the ABI Genetic 
Analyser 3130xl (Applied Biosystems, Foster City, CA, United States).
Laboratory modifications
Many laboratories required physical alterations to existing structures or reconfigurations to 
improve effective, logical sample processing. A laboratory’s ideal sample flow was 
established, beginning at the arrival bench, where samples were logged and separated as 
needed. Sample aliquots were then sent to individual laboratory stations for routine testing, 
after which samples were moved to storage and to a final station where results were 
recorded and sent to data entry staff for entry to patients’ records. For more advanced 
testing, such as deoxyrobinucleic acid polymerase chain reaction (DNA PCR), different 
steps of the assay protocol were performed in separate rooms, with access restricted to 
dedicated laboratory members in order to minimise risk of contamination.
Biosafety and fire preparedness procedures were reviewed and revised, and appropriate 
biohazard waste processing was ensured. Security of laboratories was addressed through 
both physical and policy improvements, with signage, laboratory renovations and staff 
trainings that ensured the exclusion of non-essential staff from laboratory spaces. Laboratory 
data were secured in locked locations with strict access controls and were maintained 
according to national standards.
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Supply chain
Procurement processes were developed to maximise effective purchasing of equipment and 
consumables, from expanding use of non-cold chain reagents and regular meetings with in-
country laboratory supply sales representatives to working with Supply Chain Management 
Systems (SCMS) and the Clinton Health Access Initiative (CHAI) so as to secure the 
necessary test kits. To store all materials for distribution to the sites, two warehouses were 
maintained – one in the south (Lagos) and one in the centre (Abuja) of the country. A 
programme logistics manager and head pharmacist were hired and trained, working together 
to organise and expedite distribution of supplies to the sites using programme vehicles with 
transport staff and/or by means of an express courier with a negotiated service contract.
Equipment maintenance
Maintenance of equipment is a critical aspect of ensuring strong laboratory infrastructure, 
particularly in a resource-limited setting. Most laboratories had dedicated on-site engineers 
with varying levels of expertise. In addition, programme engineers were hired to travel to 
other sites for scheduled periodic preventive maintenance as well as specific repairs. 
Retention of skilled engineers was a serious challenge and concern; accordingly, the 
programme made great efforts to build local capacity and allow flexible working hours. 
When soliciting quotes for large equipment purchases for the programme, every effort was 
made to include training for local engineers and application specialists. Programme 
engineers also traveled to the United States, Europe and elsewhere in Africa for trainings for 
specific equipment maintenance on Partec CyFlow analysers (Partec GmbH, Munster, 
Germany), Nuaire laminar flow hoods (NuAire, Inc., Plymouth, MN, United States) and the 
Roche COBAS platform (Roche GmbH, Mannheim, Germany).
Data management
The Harvard/APIN PEPFAR data management team built an easy-to-use, electronic medical 
records system that allowed for consolidation of laboratory, clinical and pharmacy 
information using the FileMaker Pro platform (FileMaker Inc., Santa Clara, CA, United 
States). Wherever possible, these key programme areas were linked by local computer 
networks within each site. Database plug-ins or utility software tools were designed in order 
to import electronic laboratory results directly into databases when possible.
Every site also had dedicated data staff to maintain the electronic patient records. All 
databases were uploaded on a weekly basis to a secure server for compilation by the 
programme data team, for reporting and monitoring purposes. In addition, all laboratories 
were equipped with an internet-connected desktop computer for laboratory members to use 
for programme-related communication and a reference resource.
Laboratory trainings
The larger tertiary laboratories carried much of the initial responsibility for training and 
mentoring their smaller secondary and primary satellite laboratories. Programme satellite 
coordinators were the principal contact persons for all laboratory personnel and 
communicated problems needing attention to either local site management or up to 
programme management.
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Laboratory quality conferences were held annually in-country, bringing members together 
from laboratories of every size. Each conference typically had 70 to 90 attendees and were 
held in various locales within Nigeria. This type of meeting was ideal for advancing overall 
laboratory quality, addressing changes to programme policy, developing consensus 
decisions and allowing smaller laboratory groups to interact closely with more experienced 
peers.
Results
In total, Harvard/APIN PEPFAR helped support and develop the infrastructure at 35 
laboratories in Nigeria. Of the 18 major sites managed, 8 were tertiary and 10 were 
secondary laboratories. In addition, the Nigerian Federal Ministry of Health designated 7 as 
Centres of Excellence. All laboratories were housed in permanent buildings with electricity, 
back-up generators, running water and basic infrastructure; a number received substantial 
upgrades to ensure successful operation and future sustainability. Notable examples of 
effective laboratory reorganisation were the infrastructure upgrades at the Jos University 
Teaching Hospital (JUTH) tertiary laboratory (Figure 2) and the logical workflow 
renovation of the molecular laboratory at the Lagos University Teaching Hospital tertiary 
laboratory (Figure 3).
All tertiary and secondary laboratory sites provided HIV serodiagnosis through rapid test 
technologies, automated haematology, clinical chemistry, laser-based CD4+ cell 
enumeration, VL quantitation and infant DNA PCR diagnosis. The primary laboratories 
provided access to HIV rapid testing, haematology, clinical chemistry and CD4+ cell count 
enumeration. Starting in late 2012, APIN upgraded to automated VL equipment, using the 
COBAS AmpliPrep/TaqMan HIV-1 test, version 2.0. All tertiary and secondary laboratories 
had the capacity for TB diagnosis with acid-fast bacilli (AFB) staining and a subset of 
tertiary laboratories developed the infrastructure and capacity for the identification of 
multidrug-resistant TB (MDR-TB) through various assays, including GeneXpert (Cepheid, 
Sunnyvale, CA, United States) and Genotype MTBDRplus (HAIN Lifescience GmbH, 
Nehren, Germany). We introduced screening of select groups at two sites for MDR-TB 
using the MTBDRplus test and proposed using this test for expanded national surveillance to 
the National TB Control programme.7 Three tertiary laboratories had ABI capillary 
sequencers (Applied Biosystems, Foster City, CA, United States) for HIV drug resistance 
testing. In support of the national early infant diagnosis (EID) programme, with the support 
of CHAI and the US Centers for Disease Control and Prevention (CDC) office in Nigeria, 
laboratories with PCR testing capacity were also able to provide EID testing of DBS 
samples. Stock rooms were also improved with greater security mechanisms, such as bars on 
all doors and windows, sturdy shelving, stock cards and clear ordering and restocking 
procedures.
By leveraging the high volume of regular laboratory tests required by the programme, 
contracts were secured for significantly reduced reagent costs from most vendors. By 
moving from a manual Dynabeads (Life Technologies, Grand Island, NY, United States) 
method for CD4+ cell count enumeration, to automated Partec CyFlow platforms, test costs 
were reduced initially from US$22.00/test to US$5.00/test, to a cost in 2012 of under US
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$2.00/test. The cost of routine chemistry tests, such as alanine aminotransferase (ALT) and 
creatinine, dropped with the implementation of automated platforms from over US$1.00/test 
to approximately US$0.29/test. VL test costs using manual Roche Amplicor kits were 
initially US$33.00/test, but by maintaining a high volume of tests over time and migrating to 
the automated Roche COBAS platform, costs were reduced to US$14.00/test by 2012.
Starting in 2010, Harvard began shifting laboratory logistics responsibilities to APIN. 
Existing vendors began to bill APIN directly, and supply chains were modified to increase 
local procurement of consumables and test kits. Changing import regulations, supplier stock-
outs and local strikes necessitated occasional aid from an established non-profit organisation 
that could provide additional mechanisms for import and customs clearance.
The achievements of the eight-year laboratory scale-up in the Harvard/APIN PEPFAR 
programme have been significant. From 2004–2012, Harvard/APIN supported laboratories 
were able to provide haematology, chemistry, CD4+ cell count enumeration and VL results 
for over 2.5 million samples (Table 2, Figure 4). The collaboration for EID testing expanded 
rapidly in Nigeria, with a greater than 10-fold increase in capacity from 2007 to 2008, when 
over 9000 HIV exposed infants were tested.
Impact on health system strengthening
Beyond improvements of specific laboratory services to support the ongoing ART 
programme, the training and mentorship activities expanded the goal of providing the 
highest quality of overall healthcare. The programme sought to extend beyond ART delivery 
and to integrate quality processes and equipment benefits throughout the hospitals and 
clinics. For example, the purchase of portable TB-diagnostic X-ray equipment became 
available for use by other hospital departments.
Training of programme staff also benefited the overall institution’s laboratory capacity-
building efforts, as most programme staff also had roles in the hospitals’ non-HIV 
laboratories. Generally, only two to three persons from each laboratory were invited to 
attend the annual group trainings; subsequently, conference attendees provided step-down 
training in order to transfer new information to the entire local laboratory team. This also 
incentivised laboratory managers to maintain high levels of performance, helping to ensure 
leadership positions for their teams in future trainings. We found the utilisation of training-
of-trainer and step-down training methods to be a very cost-effective system of providing 
training across programme laboratories and allowed for dissemination of training across 
local laboratory systems.
Training conferences
Centralised laboratory conferences provided programme management the opportunity to 
address the laboratory staff teams directly and to acknowledge and commend their hard 
work. These central workshops allowed programme staff continual assurance of 
standardisation across programme laboratories. Over time, it was realised that workshop 
participation could be strengthened through administration of pre- and post-tests 
encompassing major topics. Additionally, these meetings offered laboratory teams an 
opportunity to connect with others that were conducting similar work and allowed for 
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generation of a network that could provide local troubleshooting and support. Programme-
wide laboratory trainings were attended by 211 laboratory staff over 59 training days; and 
programme management provided direct laboratory mentorship training over 526 days. In-
country teams also developed trainings for more targeted topics such as equipment 
maintenance, new laboratory platform initiation and accreditation preparedness, training 159 
laboratory staff over 84 training days. These numbers do not account for the step-down 
training days or for retraining sessions that took place upon return to individual laboratory 
sites.
If programme management identified a laboratory with specific concerns, a site-specific 
training visit was organised. These localised trainings addressed a wide array of issues, from 
laboratory staff reorganisation, to launching a trial of a new diagnostic point-of-care 
platform, to troubleshooting an assay performing out of range. Coordination was sought 
with clinical and pharmacy training teams so as to extend laboratory topics to their trainings 
and to apprise laboratory members of any updates to other programme areas that could have 
an impact on laboratory functions, such as the introduction of new drugs or drug regimens 
with a specific toxicity concern. Internal and external trainings for laboratory engineers 
resulted in reduced service calls to factory technicians and less equipment downtime for 
sites.8 Properly-functioning equipment ensured that test kits were consumed in a timely 
manner, prior to expiration, constituting another cost-saving goal. Additionally, because of 
both interest and observed need, workshops were held to assist laboratory and research staff 
with grant writing and publication skill building.
Electronic data management
Significant gains were achieved in both electronic data capture and improving delivery of 
laboratory results to clinical staff and patients. Electronic data capture decreased the 
opportunity of transcription errors and allowed laboratory staff more time for laboratory 
activities. Laboratory result turnaround times were reduced by an average of two days 
through the use of electronic data, compared with the prior method that consisted of only 
handwritten logs and manual transcription.
An advantage of creating a programme-specific database system was that it offered great 
flexibility, allowing data managers to revise clinical chemistry results to be reported in units 
that conformed to international standards, or the ability to introduce modifications rapidly as 
laboratory technologies evolved. For example, the databases were adapted to produce pop-
up flags for critical values, such as low haemoglobin or elevated liver or renal enzymes. 
Another unique electronic tool was the ‘Viral Load Utility’, created to convert analyser data 
into standardised test results for direct database import. Additionally, the database system 
was flexible enough to allow for transfer of data to national forms and provide aggregate 
reporting, when the Federal Ministry of Health developed new registers and aggregate 
reporting forms.
A major innovation by the Harvard/APIN PEPFAR laboratory and data teams was the 
design and implementation of an electronic database for both compiling patient laboratory 
information and then distributing reports over local networks to clinic and pharmacy 
locations. This ‘Treatment Response Utility’ tool was developed primarily to provide 
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medical staff with a comprehensive picture of a patient’s treatment profile over time and to 
transfer a greater number of laboratory results presented in a more useful format to the 
clinical decision-making team (Figure 5).
The utility provides a graphical layout that displays a timeline with VL, CD4+ cell count 
and drug pick-up data, as well as links to a more detailed clinical history for a particular 
patient. The visual snapshot aids the physicians in communicating and educating the patient 
on the positive health effects of ARV drug adherence. The tool also assists clinicians in 
detecting failure of a drug regimen, assisting in a more rapid switch to a new drug regimen, 
or intervening for patients struggling with adherence.
Laboratory quality control and accreditation
At the onset of the Harvard/APIN PEPFAR programme, very few laboratories had quality 
management systems in place. As laboratories became equipped and staff were trained, data 
quality processes and laboratory quality assurance systems were instituted. In-country 
external quality assurance (EQA) was scaled up, with distribution of standardised controls 
for VL testing. Harvard/APIN PEPFAR-supported laboratories subscribed to EQA 
programmes distributed by the College of American Pathologists for blood chemistry and 
viral markers, as well as the United Kingdom National External Quality Assessment Service 
for CD4+ cell count monitoring. In addition, EQA for EID through DBS testing was 
conducted through the International Laboratory Branch of the CDC’s Division of Global 
HIV/AIDS. An EQA programme was not available for the ViroSeq drug resistance 
genotyping; however, genotyping and sequence analysis were verified at Harvard. Whilst 
being costly, the international EQA programmes were a requirement of laboratory 
accreditation programmes, and resulted in marked improvements in reported results for all 
laboratories by the second year of subscription. Since 2009, addressing long-term 
sustainability, the Harvard/APIN PEPFAR laboratories have partnered with the Nigerian 
National External Quality Assessment Laboratory, managed by the Medical Laboratory 
Science Council of Nigeria, to expand an accredited national EQA programme in lieu of 
international subscriptions.
The SLMTA programme was launched in Kigali, Rwanda in 2009 by the WHO Regional 
Office for Africa (WHO AFRO), the CDC, the CHAI and the American Society for Clinical 
Pathology in an effort to promote accessible pathways to accreditation in sub-Saharan 
Africa.1 Six laboratories from the Harvard/APIN programme were selected for inclusion in 
the initial SLMTA rollout in 2010. These initial laboratories were nominated by the 
government of Nigeria and CDC’s office in Nigeria and achieved marked improvements 
from 2010 to 2012 (Table 3).
Six tertiary laboratories enrolled in the initial SLMTA rollout in 2010 and achieved exit 
scores of five stars (one laboratory) and four stars (five laboratories) on a five-star scale. The 
one five-star laboratory has also been ISO 9001 certified and plans are in place to move 
additional secondary laboratory sites into future SLMTA quality assessment programmes.9 
This programme has served as a springboard, not just for the initial laboratories enrolled, but 
also for all laboratories in the Harvard/APIN programme, to focus on the WHO AFRO 
assessment scheme and to make dramatic improvements to laboratory quality processes.
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Discussion
Quality laboratory services have become a foundation of the Harvard/APIN PEPFAR 
programmes in Nigeria and capacity has grown to include automated clinical chemistries 
and haematology for monitoring ART toxicity at 24 laboratories, PCR-based VL monitoring 
and EID at 10 laboratories and capillary-based genetic sequencing for HIV drug-resistance 
mutations at 3 laboratories. Over the course of the programme, the number of patients 
supported with HIV care rose from 2439 in 2004 to 159 897 by 2012 and our programme 
laboratories provided over 2.5 million laboratory test results for these patients. In addition, 
many sites achieved documented improvements in quality services as they moved through 
the SLMTA programme toward accreditation.
Many of the outcomes detailed in this article originated from major international 
investments to expand global health programmes in the developing world (eg. PEPFAR). 
Such scale-ups could represent an opportunity to apply proven methods and novel 
approaches to effect meaningful improvement in local laboratory capacities. Sustainability 
of all laboratory improvement endeavours must be considered carefully, with attention being 
given to the realities of economic constraints, transitions to in-country support and 
management and integration with national strategic plans. It is critical to build a solid 
foundation of local laboratory leadership that can maintain improvements independently 
when international teams depart. The authors believe that without the described 
improvements to laboratory capacity and quality, the growth and achievements of the 
Harvard / APIN PEPFAR programme could not have been attained.
Various processes of the 12 quality system essentials that we used to scale up laboratory 
activities were effective. Specifically, using multiple training methods worked well in 
ensuring sufficient numbers of trained laboratory staff at each site along with maintenance 
of high-quality, standardised services throughout the programme sites. The system of 
centralised procurement and supply distribution allowed for efficient monitoring of supply 
use and reduction in costs through bulk ordering. By implementing an electronic medical 
record system, we ensured increased use of data by clinical staff for improved patient care. 
Furthermore, laboratory teams elevated the overall quality of care at the sites by providing 
data readily accessed by the electronic Treatment Response Utility. The training efforts also 
resulted in personnel that were able to develop and maintain laboratories worthy of 
international accreditation. Additionally, the laboratory scale-up and training efforts had 
many indirect effects. One major impact of the laboratory scale-up efforts was concomitant 
health system strengthening across the hospital settings in which our HIV programmes were 
located. Other groups have documented similarly that the PEPFAR scale-up and integration 
within existing healthcare systems has improved the linkage of HIV and TB care10 and 
increased the number of in-hospital births in resource-limited settings.11
In addition, as a result of PEPFAR-associated training efforts, various programme-affiliated 
laboratory researchers from Nigeria have been successful in gaining Fogarty Fellowships 
(Fogarty International Center, NIH, Bethesda, MD, United States) to spend several months 
working on research projects in the Harvard research laboratories in Boston, MA, United 
States. The Harvard/APIN PEPFAR team has published research in peer-reviewed journals 
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supporting the cost effectiveness and patient benefit from regular VL and drug resistance 
monitoring.12,13 Finally, Harvard worked with APIN to expand testing capabilities by 
distribution of point-of-care equipment (including the Partec CyFlow miniPOC) and are 
embarking on a new programme to test a point-of-care technology for measuring VLs in an 
African resource limited setting.14
Conclusion
In this article we have provided an overview of methods that may be useful in the 
development and support of a sustainable laboratory infrastructure, whilst simultaneously 
developing quality processes through a quality management system model and building 
upon the existing physical and human capital in a resource-limited setting such as Nigeria. 
Looking forward, as PEPFAR’s reorganisation of management by implementing partners 
occurs, APIN endeavours to apply these strategies to strengthen laboratories at the hospitals 
it inherits and hopes that new partners at ceded locations continue to do the same. We hope 
that many of these lessons learned and strategies employed may assist and encourage the 
development of other laboratories in resource-limited settings.
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FIGURE 1. 
Illustration of hub-and-spoke laboratory organisation.
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FIGURE 2. 
Infrastructure updates made to Jos University Teaching Hospital in Jos, Plateau State.
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FIGURE 3. 
Diagram of the molecular biology laboratory renovations, produced in collaboration with 
US Centers for Disease Control and Prevention, for directional workflow at the Lagos 
University Teaching Hospital, Lagos State.
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FIGURE 4. 
Cumulative laboratory tests performed by Harvard/APIN PEPFAR laboratories.
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FIGURE 5. 
Example of a patient history in the treatment response utility.
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